en · de · es · fr · pt
cardarine-notes.peptides3081.com › Info › Identity And Pharmacological Classification — Field Notes

Identity And Pharmacological Classification — Field Notes

By Editorial Desk · published 2025-08-16 · last reviewed 2025-09-15 · Info

Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.

Identity and Pharmacological Classification

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

Mechanism and Safety Research

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

Cardarine at a glance

PropertyValueNotes
Chemical classPPARδ agonistNot an anabolic steroid.
Common synonymsGW501516, GW-1516Cardarine is an informal name.
AppearanceWhite to off-white powderTypical for research-grade solid.
Solubility classPoorly soluble in water; soluble in some organic solventsSuch as DMSO or ethanol in laboratory settings.
Typical storage temperatureCool, dry, protected from lightSpecific conditions vary by supplier and form.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Related pages on this site

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Background and Regulatory History

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

Cardarine Identity and Mechanism

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Background from the literature

Cárdenas' capture in 2003 and extradition in 2007 weakened the cartel, but the resulting fragmentation and the independence of Los Zetas intensified violence in the context of the drug war, leaving a lasting legacy of conflict in Mexico in the decades that followed. Following the capture of Osiel Cárdenas Guillén in 2003 and his extradition in 2007, leadership fell to Jorge Eduardo Costilla Sánchez, a key figure in the Gulf Cartel, who led the criminal organization until 2012. Internal dynamics and rivalries, especially with Los Zetas, defined his era. The pursuit of Joaquín "El Chapo" Guzmán from 2001 to 2014 is a pivotal case in the context of the 21st-century global war on drugs, as it exemplifies the challenges of combating sophisticated transnational criminal organizations. Guzmán, as the leader of the Sinaloa Cartel, orchestrated one of the most powerful drug trafficking networks, responsible for smuggling vast quantities of narcotics into the United States and Europe, generating billions in illicit revenue. His 2001 escape from a high-security Mexican prison and subsequent evasion until his 2014 capture highlighted the systemic corruption, institutional weaknesses, and cross-border complexities that hinder effective counter-narcotics strategies. The operation to apprehend him, involving Mexican authorities and U.S.

Ammonium acetate, also known as spirit of Mindererus in aqueous solution, is a chemical compound with the formula NH4CH3CO2. It is a white, hygroscopic solid and can be derived from the reaction of ammonia and acetic acid. It is available commercially.

== Benefits to fresh produce == Modifying the atmosphere inside fresh produce packaging to provide lowered levels of O2 and elevated levels of CO2 is beneficial for many fresh produce items and "can reduce respiration, decrease ethylene production and action, retard tissue ripening and softening, retard chlorophyll degradation and biosynthesis of carotenoids and anthocyanins, reduce enzymatic browning, alleviate physiological disorders and chilling injury, retard development of decay, and maintain nutritional quality of produce. The effect of decreased O2 and increased CO2 on senescence and ripening process are additive and can be synergistic." "In vegetative tissues MAP can also reduce leaf regrowth (green onion and leek), stem toughening (asparagus), and leaf sprouting and rooting in root vegetables (parsnip, radishes). The delay of ripening and senescence of fruits and vegetables also reduces their susceptibility to pathogens."

=== Bio-based electronics and energy storage === Nanocellulose can pave the way for a new type of "bio-based electronics" where interactive materials are mixed with nanocellulose to enable the creation of new interactive fibers, films, aerogels, hydrogels and papers. E.g. nanocellulose mixed with conducting polymers such as PEDOT:PSS show synergetic effects resulting in extraordinary mixed electronic and ionic conductivity, which is important for energy storage applications. Filaments spun from a mix of nanocellulose and carbon nanotubes show good conductivity and mechanical properties. Nanocellulose aerogels decorated with carbon nanotubes can be constructed into robust compressible 3D supercapacitor devices. Structures from nanocellulose can be turned into bio-based triboelectric generators and sensors. In April 2013 breakthroughs in nanocellulose production, by algae, were announced at an American Chemical Society conference, by speaker R. Malcolm Brown, Jr., Ph.D, who has pioneered research in the field for more than 40 years, spoke at the First International Symposium on Nanocellulose, part of the American Chemical Society meeting. Genes from the family of bacteria that produce vinegar, Kombucha tea and nata de coco have become stars in a project — which scientists said has reached an advanced stage - that would turn algae into solar-powered factories for producing the "wonder material" nanocellulose.

Sources: en.wikipedia.org

Reference notes

Even during digestion, in general, one or two hours following a meal, insulin release from the pancreas is not continuous, but oscillates with a period of 3–6 minutes, changing from generating a blood insulin concentration more than about 800 p mol/l to less than 100 pmol/L (in rats). This is thought to avoid downregulation of insulin receptors in target cells, and to assist the liver in extracting insulin from the blood. This oscillation is important to consider when administering insulin-stimulating medication, since it is the oscillating blood concentration of insulin release, which should, ideally, be achieved, not a constant high concentration. This may be achieved by delivering insulin rhythmically to the portal vein, by light activated delivery, or by islet cell transplantation to the liver.

Both morphine and 6-MAM are μ-opioid agonists that bind to receptors present throughout the brain, spinal cord, and gut of all mammals. The μ-opioid receptor also binds endogenous opioid peptides such as β-endorphin, leu-enkephalin, and met-enkephalin. Repeated use of heroin results in a number of physiological changes, including an increase in the production of μ-opioid receptors (upregulation). These physiological alterations lead to tolerance and dependence, so that stopping heroin use results in uncomfortable symptoms including pain, anxiety, muscle spasms, and insomnia called the opioid withdrawal syndrome. Depending on usage it has an onset 4–24 hours after the last dose of heroin. Morphine also binds to δ- and κ-opioid receptors. There is also evidence that 6-MAM binds to a subtype of μ-opioid receptors that are also activated by the morphine metabolite morphine-6β-glucuronide but not morphine itself. The third subtype of third opioid type is the mu-3 receptor, which may be a commonality to other six-position monoesters of morphine. The contribution of these receptors to the overall pharmacology of heroin remains unknown. A subclass of morphine derivatives, namely the 3,6 esters of morphine, with similar effects and uses, includes the clinically used strong analgesics nicomorphine (Vilan), and dipropanoylmorphine; there is also the latter's dihydromorphine analogue, diacetyldihydromorphine (Paralaudin).

=== The Squibb Institute for Medical Research, New Jersey === Ondetti had multiple obstacles to overcome to work in the US. Primarily, most of Ondetti's English experience had been from chemistry textbooks. Surprisingly, Ondetti's largest language barrier was not Spanish to English, but adjusting from British to American English. Fortunately, he found an English tutor in America. Overall, Ondetti enjoyed his move to America, citing the ease of finding a car and an apartment as examples. The research which Ondetti worked on was also improved. Instead of sending samples to the United States from Argentina, he brought them down the hall. Ondetti was placed in the peptide synthesis research group. As opposed to his initial reaction to carbohydrate chemistry, he was pleased because he enjoyed contact with biologists. Over the next nine years, Ondetti gained recognition in peptide synthesis and the position as peptide chemistry chair. After this promotion, Miguel and his wife, Josephine, definitely decided to stay in America after considering the possibility of moving back during the original move. During the 1960s, peptides were considered valuable drug candidates. Ondetti's group researched synthesis of insulin and venom peptides. In the mid 1960s, the director created a task force to work on peptides. In this rearrangement, Ondetti came to work with Emily Sabo. During Squibb's effort to synthesis secretin, Ondetti stopped carrying a lab notebook. He considered Sabo to be such an accurate and skilled chemist, that he let her do all the experiments.

For example, some cells in a developing embryo migrate along specific pathways by matching the orientation of their microfilaments to the "grain" of fibers in the ECM. Researchers are also learning that the ECM around a cell can influence the activity of genes in the nucleus. Information about the ECM probably reaches the nucleus by a combination of mechanical and chemical signaling pathways. Mechanical signaling involves fibronectin, integrins, and microfilaments of the cytoskeleton. Changes in the cytoskeleton may in turn trigger chemical signaling pathways inside the cell, leading to changes in the set of proteins being made by the cell and therefore changes in the cells function. In this way, the ECM of a particular tissue may help coordinate the behavior of all the cells within that tissue. Direct connections between cells also function in this coordination.

== Interactions == Atomoxetine is a substrate for CYP2D6. Concurrent treatment with strong CYP2D6 inhibitors such as bupropion, fluoxetine, paroxetine, and quinidine has been shown to substantially increase atomoxetine exposure, as well as increase N-desmethylatomoxetine levels and decrease 4-hydroxyatomoxetine levels. Bupropion increased atomoxetine exposure by 5.1-fold and decreased 4-hydroxyatomoxetine-O-glucuronide exposure by 1.5-fold. Similarly, paroxetine increased atomoxetine steady-state peak levels by 3.5-fold, total exposure (over 12 hours) by 6.5-fold, and elimination half-life by 2.5-fold. Findings were analogous for fluoxetine and quinidine. CYP2D6 inhibitors do not appear to affect atomoxetine metabolism in CYP2D6 poor metabolizers. Dosage adjustment of atomoxetine may be necessary in people taking strong CYP2D6 inhibitors. Atomoxetine does not show clinically important inhibition or induction of cytochrome P450 (CYP450) enzymes including CYP1A2, CYP3A, CYP2D6, and CYP2C9. It did not affect the pharmacokinetics of the CYP2D6 substrate desipramine, whereas it increased exposure to the CYP3A4 substrate midazolam by only 15%. Atomoxetine is a moderate to potent inhibitor of P-glycoprotein. Other notable drug interactions include:

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Is cardarine a steroid?

No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.

Has cardarine been approved for human use?

No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Network